Introduction {#s1}
============

Lung cancer is the most common type of cancer worldwide with an estimation of 1.82 million new cancer cases diagnosed. It is the leading cause of cancer-related deaths \[[@R01]\]. Lung cancers are mainly classified into two major types including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), mainly consists of adenocarcinoma and squamous cell carcinoma \[[@R02]\]. Tobacco smoking is a widely recognized risk factor for lung cancer in squamous cell carcinoma and SCLC, but smoke exposure seems to be a less potent oncogenic factor for adenocarcinoma. Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase. It has been identified as highly expressed in cancer cells including lung cancer also \[[@R03]\]. EGFR is a transmembrane protein having an extracellular ligand-binding domain, a transmembrane domain, an intracellular tyrosine kinase (TK) domain and a regulatory region \[[@R04]\]. After binding to the ligands specific tyrosine residues of the intracellular domain, it becomes autophosphorylated and results in the initiation of the intracellular signaling cascade including the Ras/Raf/MAPK, JAK/STAT and PI3K-Akt pathways which leads to the cell proliferation, cell differentiation, angiogenesis, metastasis and antiapoptosis \[[@R05]\]. The discovery of oncogenic driver mutations in the *EGFR* gene of exons 18-21 and approval of agents which target against these molecular drivers have revolutionized the management of NSCLC \[[@R06]\]. Small molecule tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib have been targeted against the EGFR, significantly improved the response rates and progression-free survival when used in patients with activating mutations of the *EGFR* gene \[[@R07]\]. Gefitinib is an orally active EGFR TK inhibitor, which has been widely used in clinical trials and approved for the treatment of advanced NSCLC \[[@R08]-[@R10]\]. Since surgical intervention, platinum-based chemotherapy and radiotherapy were the principal available therapeutic options available for the treatment of lung cancer, but with the description of *EGFR* mutations in lung adenocarcinoma in the past decade and the response of these tumors to TKIs such as gefitinib and erlotinib, a new hope in making a significant difference in the survival of such patients has arisen \[[@R11], [@R12]\]. In this study we determine the *EGFR* mutation status in NSCLC patients to investigate the association between the *EGFR* mutation and clinicopathological characters of patient.

Materials and Methods {#s2}
=====================

The study was conducted at the Department of Respiratory Medicine, King George's Medical University, Lucknow, India. The study was approved by the ethics committee of the corresponding institute and all the subjects gave their written consent. This study included only lung cancer patients; and subjects having other disorders such as chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, interstitial lung disease and other malignancies were excluded from the study. Tissue samples of the lung cancer subjects were collected bronchoscopically for the detection of *EGFR* mutations. The *EGFR* mutation was detected by immunohistochemistry (IHC) method.

Formalin-fixed, paraffin-embedded tissue sections were cut into 4-µm-thick sequential sections. After deparaffinization and rehydration, sections were boiled in citrate buffer (0.01 M, pH 6.0) for antigen retrieval. Sections were then incubated with 3% H~2~O~2~ and 5% serum to block endogenous peroxidase activity and non-specific binding. Two primary antibodies (delE746-A750 mutation specific monoclonal antibody (6B6) and L858R mutation specific monoclonal antibody (43B2); Cell Signaling Technology, Danvers, MA, USA) were used for detection of *EGFR* mutation. The sections were then incubated with biotinylated secondary antibodies and visualized by DAB. Counterstaining was carried out with hematoxylin. The sections were dehydrated in alcohol and mounted with DPX.

The IHC staining score was based on the staining intensity and percentage positivity (0-100%) of cells in the membrane and/or cytoplasm of tumor cells. Four grades were employed: 0, 1+, 2+, and 3+. 0 means no staining; 1+ means faint membrane and/or cytoplasmic staining in less than 10% positive cells; 2+ means moderate membrane and/or cytoplasmic staining in greater than 10% and less than 50% cells; 3+ means strong membrane and/or cytoplasmic staining more than 50% cells positive. 0 and 1+ scores were considered as negative; whereas 2+ and 3+ were considered as positive cases.

Data were analyzed using Graph pad prism statistical software (version 5). Descriptive data were presented as mean, standard deviation (SD) or as percentages. Comparison between the groups was done using the Chi-square/Fishers exact test for categorical variables. P value \< 0.05 was defined as being statistically significant.

Results {#s3}
=======

The demographic and clinical characteristics of lung cancer patients and controls are shown in [Table 1](#T1){ref-type="table"}. The mean age of the lung cancer patients was 53.67 years old; Out of the 70 lung cancer patients 52 (80.4%) patients were male, and 18 (19.6%) were female. In the present study the highest percentage of the lung cancer patients were non-smokers and comprises 39 (55%) of the patients. Most of the lung cancer patients were of stage III/IV which consist of 69 (98.57%) of patients. Fifty-eight (89.23%) of the patients have the clinical symptoms of cough followed by chest pain and breathlessness comprising 53 (81.54%).

###### Demographic and Clinical Profile of Lung Cancer Patients

  Parameter            Lung cancer (N = 70)
  -------------------- ----------------------
  Age (years)          53.67 ± 11.29
  Sex                  
    Male               52 (74.29%)
    Females            18 (25.71%)
  Height               157.28 ± 7.71
  Weight               46.84 ± 9.98
  BMI                  18.84 ± 3.34
  Smoking history      
    Smokers            7 (10%)
    Ex-smokers         24 (34%)
    Non-smokers        39 (55%)
  Clinical staging     
    I/II               1 (1.43%)
    III/IV             69 (98.57%)
  Clinical symptoms    
    Cough              58 (89.23%)
    Chest pain         53 (81.54%)
    Breathlessness     53 (81.54%)
    Fever              37 (56.92%)
    Hemoptysis         22 (33.86%)
    Loss of appetite   43 (66.15%)
    Change in voice    8 (12.31%)
    Vomiting           6 (9.23%)

In this study *EGFR* mutation was found in 34.29% (24/70) of NSCLC cases. [Figure 1](#F1){ref-type="fig"} represents the E746-A750 and L858R positive and negative mutation. The mean age of mutation positive and negative cases are (55.58 ± 9.39) and (53.67 ± 10.93). No statistically significant difference between age of the lung cancer patient and *EGFR* mutation status was found (P = 0.4647). Out of female included in the study, 50% (9/18) females showed *EGFR* mutation positive compared to 28.85% (15/52) of males and the association was statistically non significant (P = 0.614) ([Table 2](#T2){ref-type="table"}). Out of the non-smokers included in the study, 46.15% (18/39) showed *EGFR* mutations positive compared to 28.57% (2/7) of the smoker and 16.7% (4/24) ex-smokers groups which shows statistically significant difference (P \< 0.05) ([Table 2](#T2){ref-type="table"}). There is no statistically significant association between stage of the tumor and *EGFR* mutation status observed (P = 0.457).

![(a, b) Showing positive and negative *EGFR* mutation of E746-A750 in exon 19, and (c, d) showing positive and negative *EGFR* mutation of L858R mutation in exon 21.](wjon-09-151-g001){#F1}

###### Clinical Characteristics of Lung Cancer Patients Having Positive and Negative *EGFR* Mutations

  Parameters         Mutation positive (N = 24)   Mutation negative (N = 46)   P value
  ------------------ ---------------------------- ---------------------------- ---------
  Age                55.58 ± 9.39                 53.67 ± 10.93                0.4647
  Sex                                                                          
    Male             15 (62.5%)                   37 (80.43%)                  0.614
    Females          9 (37.5%)                    9 (19.57%)                   
  Religion                                                                     
    Hindu            23 (95.83%)                  41 (89.13%)                  0.654
    Muslim           1 (4.17%)                    5 (10.87%)                   
  Smoking history                                                              
    Smokers          2 (8.33%)                    5 (10.87%)                   \< 0.05
    Ex-smokers       4 (16.67%)                   20 (43.48%)                  
    Non-smokers      18 (75%)                     21 (45.65%)                  
  Clinical staging                                                             
    I/II             0 (0%)                       1 (2.17%)                    0.4578
    III/IV           24 (100%)                    45 (97.83%)                  

The study shows that exon 21 mutation was found in 85.8% (6/7) of male and 14.2% (1/7) of females while mutation in exon 19 was seen in 57.8% (11/19) in males and 42.1(8/11) of females. No statistically significant difference between type of *EGFR* mutation, gender (P = 0.1362), smoking status (P = 0.6404) and histological subtypes (P = 0.4438) of the tumors was observed ([Table 3](#T1){ref-type="table"}).

###### Relationship Between the Type of *EGFR* Mutation and Clinicopathological Characters of Lung Cancer Patients

  Parameters     (L858R) exon 21 mutation (N = 5)   (E746-A750) exon 19 mutation (N = 19)   P value
  -------------- ---------------------------------- --------------------------------------- ---------
  Gender                                                                                    
    Male         4 (80%)                            11 (57.9%)                              0.614
    Female       1 (20%)                            8 (42.1%)                               
  Smoking                                                                                   
    Smoker       1 (20%)                            1 (5.3%)                                0.127
    Ex-smokers   2 (40%)                            2 (10.5%)                               
    Non-smoker   2 (40%)                            16 (84.2%)                              

It has been observed from the study that deletion mutations in exon 19 was the most common and seen in 79.17 % (19/24) of the cases ([Fig. 2](#F2){ref-type="fig"}). Out of all the mutation positive cases, 20.83% (5/24) had L858R point mutations of exon 21 ([Fig. 2](#F2){ref-type="fig"}).

![Showing the NSCLC patients having positive *EGFR* mutations of exon 21 (L858R) and exon 19 (E746-A750).](wjon-09-151-g002){#F2}

Discussion {#s4}
==========

*EGFR* mutation status is the most valuable indicator for the screening of NSCLC patients. It has been reported that mutations in exon 19 were the most common of all *EGFR* mutations. Higher prevalence of *EGFR* mutations is reported in females, non-smokers and patients with adenocarcinoma by the previous study \[[@R13]\]. Lung adenocarcinoma from non-smoker and female gender are more likely to contain mutations in the *EGFR* gene and therefore may show a better response to gefitinib. In the present study the *EGFR* mutations were present in highest percentage in the male sex and in non-smokers.

Since no correlation between the presence of *EGFR* mutations and the stage of disease was found in this study hence *EGFR* mutation is an early event that plays an important role in the pathogenesis of lung adenocarcinoma.

It has been reported from the previous study that *EGFR* mutations is found in 40-55% of adenocarcinoma \[[@R14], [@R15]\]. The prevalence of *EGFR* gene mutations in NSCLC cases has been reported from 3% to 40% by previous studies worldwide \[[@R11]-[@R15]\]. In this study *EGFR* mutation is found in 36 % of NSCLC patients.

It has been reported from the previous studies that in frame deletions in exon 19 was present in 26-79% while the point mutations in exon 21 (L858R) was seen in 13-47% \[[@R16]\]. It have been reported from the previous studies that exon 19 deletions was more susceptible to gefitinib than tumors with exon 21 point mutations \[[@R17]\]. In the present study in frame deletion of exon 19 mutation was the most common *EGFR* mutations seen in 79.17 % of the cases, point mutations in exon 21 (L858R) observed in 20.83% cases which show similarity with the previous studies. Mutations in the *EGFR* gene have been reported to be associated with response of lung cancer patients to TKI such as gefitinib \[[@R9], [@R18]\]. Although the recent advances are applicable for the management of advanced NSCLC, the cure rate remains still low; hence further molecular investigations are required for the development of the new treatment strategies to improve the prognosis of lung cancer patients. It has been shown by several studies that the *EGFR* mutations are predictive factors of response to EGFR-TKI treatment. The testing of NSCLC patients with adenocarcinoma subtype of the lung for selection of specific therapy is standard of care in clinical practice. Most of the lung cancer patients where only small biopsies or cytological material are available that may benefit from molecular testing to determine the choice of drugs for target therapy \[[@R19]\].

Conclusions {#s4a}
-----------

In frame deletion of exon 19 mutation was the most common *EGFR* mutation, and *EGFR* mutations were significantly associated with female sex, non-smoker and adenocarcinoma subtypes. The analysis of *EGFR* mutation by the IHC method is a potentially useful tool to guide clinicians for personalized treatment of NSCLC patients of adenocarcinoma subtype. *EGFR* mutation status is the most valuable indicator for the screening of NSCLC patients for TKI therapy. The detection of *EGFR* mutations in NSCLC patients is helpful in selection of targeted therapy.
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